The Frederick National Laboratory is a founding member of the Accelerating Therapeutics for Opportunities in Medicine (ATOM) Consortium, a public-private partnership with the mission of transforming drug discovery by accelerating the development of more effective therapies for patients.
The ATOM Consortium was officially established in October 2017. Founding members are GSK, Lawrence Livermore National Laboratory, Frederick National Laboratory for Cancer Research, and the University of California, San Francisco (UCSF).
ATOM scientists aim to create a new pre-competitive platform for drug discovery that integrates high-performance computing, diverse biological data sets, and emerging biotechnologies.
This new platform will ultimately be offered as a shared national resource to accelerate drug discovery, transforming the process from a slow, sequential, and high-failure undertaking into a rapid, integrated, and patient-centric model.